Xcout Intel
BioTime
BioTime, Inc. was a U.S. biotechnology company focused on developing regenerative-medicine and cell-based therapies for serious medical conditions. In 2019, it changed its name to Lineage Cell Therapeutics, which continues developing cell therapies for patients with conditions including spinal cord injury, retinal disease, and cancer.
Subscribe to see BioTime’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BioTime at a glance
BioTime is a biotechnology company headquartered in United States. It has raised at least $18M across the 2 funding rounds on record. Its most recent funding round raised $10M in August 2017. Xcout tracks 2 named people at BioTime, including Lachman Lund (Dpharm, Bcom).
BioTime leadership
- Lachman LundDpharm, Bcom
- Nitesh LuandBpharm, MS
BioTime funding rounds
At least $18M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $10M | 1 named | |
| — | $8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
BioTime competitors
A few of BioTime's closest competitors — see the full list of competitors and alternatives →
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Cell Research Corporation is a biotechnology company specializing in umbilical cord lining stem cell technology and banking. The company provides products, services, and contract research related to stem cell applications for wound healing, regenerative medicine, and cosmeceuticals.
CBMG Holdings, formerly known as Cellular Biomedicine Group, is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies for cancers and stem cell therapies. The company focuses on immune cell therapies and T cell-based therapeutics. It has subsequently announced a name change to AbelZeta Pharma, Inc.
CiRC Biosciences is a privately held regenerative medicine and cell therapy company founded in 2019 and based in Chicago, Illinois, focused on developing cellular reprogramming solutions for degenerative diseases.
Link Cell Therapies Inc. is a platform biotechnology company maintaining its headquarters in South San Francisco, California. The company develops novel agents targeting hematologic and related diseases.
Get BioTime's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BioTime in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access